Download PDF
Pharmacopsychiatry 2001; 34(3): 85-90
DOI: 10.1055/s-2001-14283
Original Paper
© Georg Thieme Verlag Stuttgart · New York

A Comparison of Citalopram and Paroxetine in the Treatment of Panic Disorder: A Randomized, Single-Blind Study

G. Perna, A. Bertani, D. Caldirola, E. Smeraldi, L. Bellodi
  • Department of Neuropsychiatric Sciences, UniversitÄ Vita e Salute, Istituto Scientifico Ospedale San Raffaele, Milan
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Also available at
    Permissions and Reprints

Background: Serotonin Selective Re-uptake Inhibitors (SSRIs) are the drugs of choice for treating panic disorder (PD). In vitro studies have shown different pharmacodynamic profiles for SSRIs, but their clinical relevance is still unknown. Paroxetine, the SSRI with the strongest serotonergic effect, also shows significant cholinergic and noradrenergic activities. In this class of drugs, citalopram is the most selective for serotonin. We compared these two drugs and their effectiveness and tolerability in a sample of patients with PD in a two-month treatment course. Method: Fifty-eight patients with PD were randomly assigned to either the paroxetine or the citalopram treatment group in a single-blind, randomized design. Each patient was assessed at days 0, 7 and 60 by the Panic Associated Symptoms Scale (PASS), the Sheehan Disability Scale (SDS) and the Fear Questionnaire (FQ). Primary outcome measures were the percentage of patients free of panic attacks, anticipatory anxiety and phobic avoidance in the last week of the trial and the percentage of good responders, as defined by a reduction of at least 50 % from baseline of both PASS and SDS global scores at day 60. Results: At day 60, 86 % of patients receiving citalopram and 84 % of those receiving paroxetine responded well to treatment. No significant differences between the two drugs were found. Both were well tolerated, although sexual side effects and weight gain were frequent. Anticipatory anxiety decreased significantly after the first week of treatment, and no initial worsening in the panic attacks was observed. Conclusion: Paroxetine and citalopram show similar anti-panic properties and a good tolerability profile. Our results support evidence that the serotonergic system plays a significant role in the anti-panic properties of these two SSRIs.

References

  • 1 Argyle N, Deltito J, Allerup P, Nutziger D, Rasmussen S, Ayuso J L, Bech P. The Panic-Associated Symptoms Scale: measuring the severity of panic disorder.  Acta Psychiatrica Scandinavica. 1991;  83 20-26
    PubMedGoogle Scholar
  • 2 Ballenger J C, Wheadon D E, Steiner M, Bushnell W, Gergel I P. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder.  American Journal of Psychiatry. 1998;  155 36-42
    PubMedGoogle Scholar
  • 3 Bertani A, Perna G, Politi E, Bellodi L. Citalopram and panic disorder.  Depression and Anxiety. 1996;  4 253
    CrossrefPubMedGoogle Scholar
  • 4 Bertani A, Perna G, Caldirola D, Arancio C, Bellodi L. Pharmacologic effect of paroxetine, sertraline and imipramine on reactivity to the 35 % CO2 challenge: a double blind, random, placebo controlled study.  Journal of Clinical Psychopharmacology. 1997;  17 97-101
    CrossrefPubMedGoogle Scholar
  • 5 Burnham D B, Steiner M, Gergel I P, Oakes R, Bailer D C, Wheadon D E. Paroxetine long term safety and efficacy in panic disorder and prevention of relapse: a double-blind study. Presented at the American College of Neuropsychopharmacology (ACNP) San Juan, Puertorico; 1995
    Google Scholar
  • 6 Cassano G B, Petracca A, Perugi G, Nisita C, Musetti L, Mengali F, McNair D M. Clomipramine for Panic Disorder: I. The first 10 weeks of a long-term comparison with imipramine.  Journal of Affective Disorders. 1988;  14 123-127
    CrossrefPubMedGoogle Scholar
  • 7 Den Boer J A, Westenberg H G M. Effect of serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline.  International Clinical Psychopharmacology. 1988;  3 59-74
    PubMedGoogle Scholar
  • 8 Fawcett J. Suicide risk factors in depressive disorders and in panic disorder.  Journal of Clinical Psychiatry. 1992;  53 9-13
    PubMedGoogle Scholar
  • 9 Hoehn-Saric R, McLeod D R, Hispley P A. Effect of fluvoxamine on panic disorder.  Journal of Clinical Psychopharmacology. 1993;  13 321-326
    PubMedGoogle Scholar
  • 10 Humble M, Wisted B. Serotonin, panic disorder and agoraphobia: short term and long term efficacy in panic disorder.  lnternational Clinical Psychopharmacology. 1992;  6 21-39
    PubMedGoogle Scholar
  • 11 Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs).  Internations Clinical Psychopharmacology. 1994;  9 19-26
    PubMedGoogle Scholar
  • 12 Hyttel J, Arnt J, Sanchez C. The pharmacology of citalopram.  Reviews in Contemporary Pharmacotherapy. 1995;  6 271-285
    PubMedGoogle Scholar
  • 13 Johnson A M. Paroxetine: a pharmacological review.  International Clinical Psychopharmacology. 1992;  4 15-24
    PubMedGoogle Scholar
  • 14 Kahn R S, Wetzler S, van Praag H M, Asnis G M, Strauman T. Behavioral indications for serotonin receptor hypersensitivity in panic disorder.  Psychiatry Research. 1988;  25 101-104
    CrossrefPubMedGoogle Scholar
  • 15 Kent J M, Coplan J D, Martinez J, Karmally W, Papp L A, Gorman J M. Ventilatory effects of tryptophan depletion in panic disorder: a preliminary report.  Psychiatry Research. 1996;  64 83-90
    CrossrefPubMedGoogle Scholar
  • 16 Klaasen T, Klumperbeek J, Jeutz N E, van Praag H M, Griez E. Effects of tryptophan depletion on anxiety and on panic provoked by carbon dioxide challenge.  Psychiatry Research. 1998;  77 167-174
    CrossrefPubMedGoogle Scholar
  • 17 Klein D F. Delineation of two-responsive anxiety syndromes.  Psychopharmacologia. 1964;  5 397-408
    PubMedGoogle Scholar
  • 18 Klein D F. False suffocation alarm, spontaneous panic, and related condition.  Archives of General Psychiatry. 1993;  50 306-317
    PubMedGoogle Scholar
  • 19 Lecrubier Y, Bakker A, Dunbar G, Judge R. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder.  Acta Psychiatrica Scandinavica. 1997 a;  95 145-152
    PubMedGoogle Scholar
  • 20 Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder.  Acta Psychiatrica Scandinavica. 1997 b;  95 153-160
    PubMedGoogle Scholar
  • 21 Leinonen E, Lepola U, Tutonen J, Wade A G, Lehto H. Citalopram controls phobic symptoms in patients with panic disorder: randomized, controlled trial.  Journal of Psychiatry and Neuroscience. 2000;  25 24-32
    PubMedGoogle Scholar
  • 22 Leon A C, Shear M K, Portera L, Klerman G L. Assessing impairment in patients with panic disorder: the Sheehan Disability Scale.  Social Psychiatry and Psychiatric Epidemiology. 1992;  27 78-82
    CrossrefPubMedGoogle Scholar
  • 23 Lepola U, Leinonen E, Turtonen J. The effect of citalopram in panic disorder and agoraphobia: a pilot study.  Nordic Journal of Psychiatry. 1994;  48 13-17
    PubMedGoogle Scholar
  • 24 Lepola U M, Wade A G, Leinonen E V, Koponen H J, Frazer J, Sjodin I, Penttinen J T, Pedersen T, Lehto H J. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder.  Journal of Clinical Psychiatry. 1998;  59 528-534
    PubMedGoogle Scholar
  • 25 Liebowitz M R, Gorman J M. Panic and anxiety disorders. Ed Cavenar JO Philadelphia; In: Psychiatry Vol. 1. Chap. 32, JB Lippincott Company 1-13
    Google Scholar
  • 26 Lundberg D B A, Mueller R A, Breese G R. An evaluation of the mechanism by which serotonergic activation depresses respiration.  Journal of Pharmacology and Experimental Therapy. 1980;  212 397-404
    PubMedGoogle Scholar
  • 27 Marks I M, Mathews A M. Brief standard self-rating for phobic patients.  Behaviour Research and Therapy. 1979;  17 263-267
    PubMedGoogle Scholar
  • 28 Modigh K, Wetenberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder. A placebo-controlled trial.  Journal of Clinical Psychopharmacology. 1992;  12 251-261
    PubMedGoogle Scholar
  • 29 National Institute of Mental Health Research (NIMH), Department of Education and Welfare .ECDEU Assessment Manual . Eds Levin J and Guy W Rockville, MD, National Institute of Mental Health 1976
    Google Scholar
  • 30 Noyes R. Suicide in panic disorder: a review.  Psychiatry Medicine. 1990;  8 41-66
    PubMedGoogle Scholar
  • 31 Nutt D. The role of SSRIs in anxiety disorders.  European Neuropsychopharmacology. 1995;  5 260-261
    PubMedGoogle Scholar
  • 32 Olson E B, Dempsey J A, McCrimmon D R. Serotonin and the control of ventilation in the awake rat.  Journal of Clinical Investigation. 1979;  64 689-693
    PubMedGoogle Scholar
  • 33 Oehrberg S, Christiansen P E, Benke K. Paroxetine in the treatment of panic disorder: a randomised, double-blind, placebo controlled study.  British Journal of Psychiatry. 1995;  167 374-379
    PubMedGoogle Scholar
  • 34 Perna G, Bertani A, Gabriele A, Politi E, Bellodi L. Modification of 35 % CO2 hypersensitivity across one week of treatment with clomipramine and fluvoxamine: a double blind, randomized, placebo controlled study.  Journal of Clinical Psychopharmacology. 1997;  17 173-178
    CrossrefPubMedGoogle Scholar
  • 35 Price L H, Goddhard A W, Barr L. Pharmacologic challenges in anxiety disorders. Eds Bloom FE, Kupfer DJ Psychopharmacology: The fourth generation of progress. Raven Press, New York 1311-1325
    Google Scholar
  • 36 Regier D A, Narrow W, Rae D S. The epidemiology of anxiety disorders: the epidemiological catchment area (ECA) experience.  Journal of Psychiatric Research. 1990;  24 3-4
    PubMedGoogle Scholar
  • 37 Sasson Y, Iancu I, Fux M, Taub M, Dannon P N, Zohar J. A double-blind, cross-over comparison of clomipramine and desipramine in the treatment of panic disorder.  European Neuropsychopharmacology. 1999;  9 191-196
    PubMedGoogle Scholar
  • 38 Sheehan D V, Ballenger J C, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms.  Archives of General Psychiatry. 1980;  37 51-59
    PubMedGoogle Scholar
  • 39 Sheevan D V, Lecrubier Y, Janavs J, Knapp E, Weiler E, Bonora P, Sheedan M, Amorim P, Baker R, Sheehan K H, Lepine J P. Mini International Neuropsychiatric Interview. MINI, Paris/Tampa 1994
    Google Scholar
  • 40 Steiner M, Oakes R, Gergel I P, Burnham D B, Wheadon D E. A fixed dose study of paroxetine and placebo in the treatment in panic disorder. Presented at the 148th Annual Meeting of the American Psychiatric Association, Miami, Florida 1995
    Google Scholar
  • 41 Targum S D. Panic attacks frequency and vulnerability to anxiogenic challenge studies.  Psychiatry Research. 1991;  36 75-83
    CrossrefPubMedGoogle Scholar
  • 42 Targum S D, Marshall L E. Fenfluramine provocation of anxiety in patients with panic disorder.  Psychiatry Research. 1989;  28 295-306
    CrossrefPubMedGoogle Scholar
  • 43 Tesar G E, Rosenbaum J F, Pollack M H, Otto M W, Sachs G S, Herman J B, Cohen L S, Spier S A. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder.  Journal of Clinical Psychiatry. 1991;  52 69-76
    PubMedGoogle Scholar
  • 44 Thomas D R, Nelson D R, Johnson A M. Biochemical effects off the antidepressant paroxetine, a specific 5-hydroxytriptamine uptake inhibitor.  Psychopharmacology. 1987;  93 193-200
    PubMedGoogle Scholar
  • 45 Wade A G, Lepola U, Koponen H J, Pedersen V, Pedersen T. The effect of citalopram in panic disorder.  British Journal of Psychiatry. 1997;  170 549-553
    PubMedGoogle Scholar
  • 46 Wittchen H U. Natural course and spontaneous remissions of untreated anxiety disorders: results of the Munich Follow-up Study.  Eds Hand I, Wittchen HU Panic and Phobias: treatments and variables affecting course and outcome. 1988 SpringerVerlag, NewYork 3-17
    Google Scholar
  • 47 Yeregani V K, Jampala V C, Sobelewski E, Igel G. Effects of paroxetine on hearth period variability in patients with panic disorder: a study of holter ECG records.  Neuropsychobiology. 1999;  40 124-128
    PubMedGoogle Scholar
  • 48 Zitrin Z M, Klein D F, Woerner M G, Ross D C. Treatment of phobias I. Comparison of imipramine hydrochloridate and placebo.  Archives General Psychiatry. 1983;  40 125-138
    PubMedGoogle Scholar

Giampaolo Perna,MD PhD 

Dept. Neuropsychiatric Sciences
University of Milan. San Raffaele Hospital

29 via Prinetti 20127

Milan

Italy

Phone: ++39-2-26433211

Fax: ++39-2-26433265

Email: perna.giampaolo@hsr.it

      >